Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1681 • ACR Convergence 2024
Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Anna Zubrzycka-Sienkiewicz¹, Kamilla Klama², Martin Ullmann³, Corinne Petit-Frere³, Andras Illes³, Olga Menang³, Joëlle Monnet³ and Peter Baker³, ¹Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, ²Solumed Centrum Medyczne, Poznań, Poland, ³Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland
Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
Abstract Number: 1845 • ACR Convergence 2024
Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Amy Anderson¹, Luke Jones², Fiona Rayner³, Jessica Swift¹, Daniel Maunder¹, Henrique de Paula Lemos¹, David Swan⁴, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Gary Reynolds¹, Jasmine Sim¹, Andrew Melville⁵, Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Karim Raza⁷, Christopher Buckley⁸, Kenneth Baker¹, Arthur Pratt³, Andrew Filer⁷ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, Birmingham, United Kingdom, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Understanding the mechanisms that drive disease flares in patients with rheumatoid arthritis (RA) may aid in the development of biomarkers to facilitate targeted treatment…
Abstract Number: 1905 • ACR Convergence 2024
Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Bryant England¹, Austin Wheeler¹, Brent Luedders¹, Michael Duryee¹, Halie Frideres², Katherine Wysham³, grant Cannon⁴, Gary Kunkel⁵, Dana Ascherman⁶, Paul Monach⁷, Gail Kerr⁸, Andreas Reimold⁹, Joshua Baker¹⁰, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷VA Boston Healthcare System, Boston, MA, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Several peripheral biomarkers for RA-associated interstitial lung disease (RA-ILD) have been evaluated to enhance early RA-ILD identification. The MUC5B rs35705950 promoter variant, matrix metalloproteinase-7…
Abstract Number: 2121 • ACR Convergence 2024
Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
Roba Ghossan¹, OLIVIER FOGEL², Christian Roux¹ and Karine Briot¹, ¹COCHIN HOSPITAL, PARIS, France, ²AP-HP, Paris, France
Background/Purpose: Spontaneous lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…
Abstract Number: 2217 • ACR Convergence 2024
A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
Gilad Halpert¹, Eri Govrin², Boris Gilburd³, Shlomo Segev³, Omer Gendelman⁴, Abdulla Watad⁵, Yehuda Shoenfeld⁶, David Meiri⁷ and Howard Amital⁸, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Sdot Micha, Israel, ³Sheba Medical Center, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶sheba medical center , Israel, Ramat Gan, Israel, ⁷Technion-Israel Institute of Technology, Haifa, Israel, ⁸Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…
Abstract Number: 2234 • ACR Convergence 2024
Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
Sung Hae Chang¹, Yong-Beom Park², Gregory McDermott³, Misti Paudel⁴, Keigo Hayashi³, You-Jung Ha⁵, Jeong Seok Lee⁶, Min Uk Kim⁷, Chan Ho Park⁸, Sang Wan Chung⁹, Ji-Won Kim¹⁰, Jang Woo Ha¹¹, Sung Won Lee¹², Eun Ha Kang⁵, Yeon-Ah Lee¹³, Jung-Yoon Choe¹⁴, Eun Young Lee¹⁵ and Jeffrey Sparks¹⁶, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, ¹Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ²Yonsei University College of Medicine, Seoul, Republic of Korea, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Seoul National University Bundang Hospital, Seongnam, South Korea, ⁶Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, ⁹Kyung Hee University Hospital, Seoul, Republic of Korea, ¹⁰Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, ¹¹Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, ¹²Soonchunhyang University Cheonan Hospital, Seoul, South Korea, ¹³Kyung Hee University Hospital, Seoul, South Korea, ¹⁴Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ¹⁵3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ¹⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (ILD) is a heterogeneous disease with a chronic course and potential for flares. Serum biomarkers are needed to identify those…
Abstract Number: 2251 • ACR Convergence 2024
Stress-Related Neural Activity Measured with FDG-PET/CT Is Associated with Articular Disease Activity, Systemic Inflammation, and Treatment-associated Change in Arterial Inflammation in Rheumatoid Arthritis
Jon Giles¹, Joan Bathon², Katherine Liao³, Pamela Rist⁴, Shady Abohashem⁵, Michael Osborne⁵, Giovani Civieri⁵, Zahi Fayad⁶, Daniel Solomon³ and Ahmed Tawakol⁷, ¹Cedars Sinai Medical Center, Los Angeles, CA, ²Columbia University, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham & Women's Hospital/Harvard University, Boston, MA, ⁵Massachusetts General Hospital/Harvard University, Boston, MA, ⁶Mount Sinai Medical Center, New York, NY, ⁷Massachusetts General Hospital/Harvard Medical School, Boston, MA
Background/Purpose: The amygdala, a limbic structure of the brain’s salience network, links chronic external stressors with downstream effects on the HPA axis and hematopoietic tissues…
Abstract Number: 2272 • ACR Convergence 2024
Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry
Dimitrios Pappas¹, George Reed², Kevin kane³, Michael Weinblatt⁴ and Joel Kremer⁵, ¹CorEvitas, New York, NY, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Massachusetts Lowell, Lowell, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Methotrexate (MTX) continues to be the cornerstone therapy in the treatment of rheumatoid arthritis (RA) and is usually the first conventional synthetic (cs) DMARD…
Abstract Number: 2531 • ACR Convergence 2024
CRISPR Deletion Screen in Fibroblasts Identifies Novel Regulators of Inflammation
Alisa Mueller¹, Suppawat Kongthong², Angela Zou³, Gerald Watts⁴, Cassandra Murphy², Hung Nguyen², Jacqueline Perrigoue⁵, Mathew Chamberlain⁵, Kevin Wei⁶, Soumya Raychaudhuri² and Michael Brenner⁷, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Brookline, MA, ⁵Johnson & Johnson, Spring House, PA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts adopt an inflammatory phenotype that catalyzes pathogenic synovial hyperplasia and ultimately bone and cartilage destruction. However, identifying therapeutic…
Abstract Number: 2606 • ACR Convergence 2024
Changes in Long-term GC Use Among Older Adults After New Diagnosis of Late-onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Beth Wallace², Namrata Singh³, Una Makris⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Washington, Bellevue, WA, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Older adults with late-onset rheumatoid arthritis (LORA) receive less disease-modifying anti-rheumatic drugs (DMARDs), which is the standard of care. In contrast, long-term glucocorticoid (GC)…
Abstract Number: PP08 • ACR Convergence 2024
Whispers of Resilience: Navigating Life with Rheumatism
Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
Abstract Number: 0035 • ACR Convergence 2024
Anti-CCP Generation in the Female Genital Tract Is Increased During the Postpartum Period in Women Without RA
Daniele Marcy¹, Ashley Visser², Claudia Lugo², Kristin Sturm² and Kristen Demoruelle³, ¹University of Colorado Anschutz Medical Campus, Northglenn, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: It is well established that women develop RA approximately three times more often than men. In addition, several risk factors for RA uniquely effect…
Abstract Number: 0052 • ACR Convergence 2024
Single Cell RNA-sequencing Analysis Revealed Peripheral Blood and Synovial Alterations of Dendritic Cells in Rheumatoid Arthritis
Yuichi Suwa¹, Saeko Yamada¹, Toshiyuki Ushijima², Hideyuki Takahashi², Tomohisa Okamura¹, Yasuo Nagafuchi³ and Keishi Fujio⁴, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo-ku, Tokyo, Japan, ³Department of Functional Genomics and Immunological Diseases, Graduate Schoold of Medicine, the University of Tokyo, Tokyo, Japan, ⁴Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Recent single cell analyses have unveiled novel dendritic cell (DC) subpopulations that could potentially be linked to rheumatoid arthritis (RA). This study aimed to…
Abstract Number: 0130 • ACR Convergence 2024
Depression Genetic Risk, Diagnoses, and Treatments in Association with Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program
Jing Cui¹, Jeong Yee¹, Emily Oakes¹, Elizabeth Karlson¹, Leah Santacroce¹, Hongshu Guan¹, Laura D. Kubzansky², Karestan C. Koenen², Candace Feldman¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Diagnoses of depression, highly prevalent in SLE and RA populations, were associated with increased cardiovascular disease (CVD) risk in the All of Us Research…
Abstract Number: 0205 • ACR Convergence 2024
Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: A growing body of evidence highlights a link between rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].